Tetrandrine
Based on 17 publication(s) in Google Scholar
Tetrandrine (NSC-77037; d-Tetrandrine) is a bis-benzyl-isoquinoline alkaloid, which inhibits voltage-gated Ca2+ current (ICa) and Ca2+-activated K+ current.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 518-34-3
- Formula: C38H42N2O6
- Molecular Weight:622.75
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Tetrandrine
More- Nat Commun. 2023 Jan 14;14(1):226. [Abstract]
- MedComm (2020). 2025 Aug 31;6(9):e70353. [Abstract]
- Pharmacol Res. 2023 Nov:197:106955. [Abstract]
- J Pharm Anal. 2024 Oct;14(10):101036. [Abstract]
- Dev Cell. 2024 Jul 30:S1534-5807(24)00441-6. [Abstract]
- Phytomedicine. 2025 Jul:142:156713. [Abstract]
- Phytomedicine. 2025 Feb 6:139:156483. [Abstract]
- Chin Med. 2025 Oct 2;20(1):153. [Abstract]
- Front Pharmacol. 2020 Jan 10;10:1530. [Abstract]
- RSC Adv. 2026 Apr 7;16(20):18359-18373. [Abstract]
- J Inflamm Res. 2024 Dec 24:17:11485-11503. [Abstract]
- Virol J. 2025 Jun 4;22(1):181. [Abstract]
- Heliyon. 2022 Aug 13;8(8):e10201. [Abstract]
- Virology. 2022 Aug:573:12-22. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- Res Sq. 2026 Feb 1.
- bioRxiv. 2020 Jun.
-
IF
-
WB
-
WB
All Calcium Channel Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A673 | GI50 |
4 μM
Compound: 16
|
Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| CCRF-CEM | IC50 |
15.8 μM
Compound: 1
|
Antiproliferative activity against vincristine-resistant human CEM cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-blue cell viability assay
Antiproliferative activity against vincristine-resistant human CEM cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-blue cell viability assay
|
[PMID: 32942071] |
| ECa-109 cell line | IC50 |
29.37 nM
Compound: TET
|
Reversal of VCR -resistance in human Eca-109 cells assessed as vincristine IC50 by measuring cell viability incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
Reversal of VCR -resistance in human Eca-109 cells assessed as vincristine IC50 by measuring cell viability incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
|
[PMID: 36892076] |
| ECa-109 cell line | IC50 |
29.4 nM
Compound: TET
|
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
|
[PMID: 36892076] |
| HCC1806 | GI50 |
5.1 μM
Compound: 16
|
Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| HCC1937 | GI50 |
4.2 μM
Compound: 16
|
Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| HCC70 | GI50 |
3.4 μM
Compound: 16
|
Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| HEK-293T | CC50 |
>1 μM
Compound: 1; tet
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability by CellTiter-Glo assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability by CellTiter-Glo assay
|
[PMID: 37043739] |
| HEL | IC50 |
16.78 μM
Compound: Tetrandrine
|
Cytotoxicity against human HEL cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HEL cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| HEL | IC50 |
19.74 μM
Compound: Tetrandrine
|
Cytotoxicity against human HEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| HEL | IC50 |
7.45 μM
Compound: Tet
|
Antiproliferative activity against HEL cells after 48 hrs by MTT assay
Antiproliferative activity against HEL cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| HeLa | IC50 |
2.16 μM
Compound: Tetrandrine
|
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
|
[PMID: 29624387] |
| HepG2 | IC50 |
6.82 μM
Compound: Tetrandrine
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 28057423] |
| K562 | IC50 |
11.76 μM
Compound: Tet
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| K562 | IC50 |
13.81 μM
Compound: Tetrandrine
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| K562 | IC50 |
6.43 μM
Compound: Tetrandrine
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| KB | ED50 |
5800 nM
Compound: 16
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 9917283] |
| KB-V1 | ED50 |
3.7 μg/mL
Compound: 1
|
Cytotoxicity against human multidrug-resistant KBV1 cells
Cytotoxicity against human multidrug-resistant KBV1 cells
|
[PMID: 8450318] |
| L02 | IC50 |
44.25 μM
Compound: Tet
|
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| MCF7 | IC50 |
19.58 μM
Compound: Tetrandrine
|
Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| MCF7 | IC50 |
8.62 μM
Compound: Tetrandrine
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 28057423] |
| MDA-MB-231 | GI50 |
5 μM
Compound: 16
|
Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| MDA-MB-231 | IC50 |
18.45 μM
Compound: Tetrandrine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784186] |
| MDA-MB-231 | IC50 |
21.97 μM
Compound: Tetrandrine
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| MDA-MB-231 | IC50 |
8.94 μM
Compound: Tet
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| MDA-MB-453 | GI50 |
3.3 μM
Compound: 16
|
Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| P388 | ED50 |
0.4 μg/mL
Compound: 1
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 8450318] |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
10 nM
Compound: Fanchinin
|
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
|
[PMID: 15743190] |
| PC-3 | IC50 |
5.86 μM
Compound: Tet
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 30109000] |
| PC-3 | IC50 |
7.87 μM
Compound: Tetrandrine
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29133049] |
| PLC-PRF-5 | IC50 |
18.46 μM
Compound: Tetrandrine
|
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human PLC/PRF/5 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 28109948] |
| SJRH30 | GI50 |
3 μM
Compound: 16
|
Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
|
[PMID: 33226219] |
| U-937 | IC50 |
>50 μM
Compound: 16, NSC 77037
|
Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay
Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay
|
[PMID: 22766217] |
| Vero | CC50 |
14.92 μM
Compound: Tetrandrine
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
3 μM
Compound: Tetrandrine
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
| Vero C1008 | EC50 |
1.1 μM
Compound: Hanfangchin A
|
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
|
[PMID: 32511357] |
| Vero C1008 | EC50 |
1.1 μM
Compound: Hanfangchin A
|
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
|
10.1101/2020.04.16.044016 |
| VSMC | IC50 |
1.48 μM
Compound: Tetrandrine
|
Antivegetative activity against rat VSMC
Antivegetative activity against rat VSMC
|
[PMID: 20708932] |
The effects of Tetrandrine (NSC-77037), a bis-benzyl-isoquinoline alkaloid, on voltage-gated Ca2+ currents (ICa) and on Ca2+-activated K+ current (IK(Ca)) and channels in isolated nerve terminals of the rat neurohypophysis are investigated using patch-clamp techniques. The non-inactivating component of ICa is inhibited by external Tetrandrine (NSC-77037) in a voltage- and dose-dependent manner, with an IC50=10.1μM. Tetrandrine (NSC-77037) decreases the channel-open probability, within bursts, with an IC50=0.21 μM[1]. To evaluate the effects of Tetrandrine on HCC cells, Huh7, HCCLM9 and Hep3B cells are treated with 0 (DMSO), 0.5, 1, 2 or 4 μM of Tetrandrine for 24 h. The cell proliferation assay indicates that Tetrandrine exhibits almost no effect on the inhibition of HCC cell proliferation at 0.5-2 μM. However, Tetrandrine (NSC-77037) inhibits HCC cell migration in a dose-dependent manner. Furthermore, a wound-healing and transwell assay shows that 2 μM Tetrandrine significantly inhibits HCC cell migration and invasion[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 518-34-3
-
Appearance Solid
-
Molecular Weight 622.75
-
Formula C38H42N2O6
-
Color White to off-white
-
SMILES
COC1=CC(CCN(C)[C@@]2([H])CC3=CC(O4)=C(OC)C=C3)=C2C(OC5=C(OC)C=C6C([C@]([H])(CC7=CC=C4C=C7)N(C)CC6)=C5)=C1OC
-
Synonyms
NSC-77037; d-Tetrandrine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
A gain-of-function TPC2 variant R210C increases affinity to PI(3,5)P2 and causes lysosome acidification and hypopigmentation. [Abstract]2023 Jan 14;14(1):226. PMID: 36641477 -
MedComm (2020)
2025 Aug 31;6(9):e70353. PMID: 40900808 -
Pharmacol Res
Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis. [Abstract]2023 Nov:197:106955. PMID: 37820855 -
J Pharm Anal
Tetrandrine targeting SIRT5 exerts anti-melanoma properties via inducing ROS, ER stress, and blocked autophagy. [Abstract]2024 Oct;14(10):101036. PMID: 39850232 -
Dev Cell
2024 Jul 30:S1534-5807(24)00441-6. PMID: 39094564 -
Phytomedicine
Bioactive equivalent combinatorial components of Xiao-Xu-Ming decoction inhibit the calmodulin-mediated MLCK/MLC axis to attenuate coronary artery spasm. [Abstract]2025 Jul:142:156713. PMID: 40349422 -
Phytomedicine
2025 Feb 6:139:156483. PMID: 39947004 -
Chin Med
Integration of network pharmacology, transcriptomics and single-cell sequencing to explore the effect of Rougan Keli in alleviating liver cirrhosis. [Abstract]2025 Oct 2;20(1):153. PMID: 41039598 -
Front Pharmacol
Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis. [Abstract]2020 Jan 10;10:1530. PMID: 31998129
Tetrandrine purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jan 10;10:1530. [Abstract]
Tetrandrine inhibits osteoclast function in vitro A) Tetrandrine suppresses RANKL-induced actin ring formation in BMMs. Osteoclasts having actin rings and nucleuses inside these osteoclasts are counted.
Tetrandrine purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jan 10;10:1530. [Abstract]
Phosphorylation of key proteins in NF-kB pathways, including P50, P65 and IκBα, are detected by Western blotting.
Tetrandrine purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jan 10;10:1530. [Abstract]
RAW264.7 cells are harvested after induced by RANKL (50ng/mL) and tetrandrine (0, 0.125, 0.25, 0.5 ,1μM) for 5days. The proteins were used to detect osteoclastogenic proteins levels of NFATc1, CTR9, CTSK, TRAP, and MMP9. D) Tetrandrine down‐regulates osteoclastogenic gene expression of NFATc1, TRAP, CTSK, and c-fos. RAW264.7 cells are stimulated with RANKL and cultured with different concentrations of tetrandrine.
-
RSC Adv
A multi-stage computational pipeline and in vitro validation for the discovery of small-molecule translation inhibitors targeting the bacterial ribosome. [Abstract]2026 Apr 7;16(20):18359-18373. PMID: 41953617 -
J Inflamm Res
Single-Cell Sequencing and Machine Learning Integration to Identify Candidate Biomarkers in Psoriasis: INSIG1. [Abstract]2024 Dec 24:17:11485-11503. PMID: 39735895 -
Virol J
Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification. [Abstract]2025 Jun 4;22(1):181. PMID: 40468427 -
Heliyon
Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology, molecular docking and experimental verification. [Abstract]2022 Aug 13;8(8):e10201. PMID: 36046534 -
Virology
2022 Aug:573:12-22. PMID: 35690007 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
-
Solvent & Solubility
DMSO : 5 mg/mL (8.03 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Protocol
Huh7, HCCLM9 and Hep3B cells are seeded in a 96-well plate at a cell density of 5 × 103 cells/well. The cells are treated with the indicated concentrations (0-4 μM) of Tetrandrine (NSC-77037) for 24 h. The cells are subsequently stained with 20 μL of MTS for 1-2 h, and the plates are read at 490 nm on a BioTek ELx800[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Four-week-old male athymic BALB/c nu/nu SPF mice (body weight range from 18 g to 20 g) are used. HCCLM9 WT and HCCLM9 ATG7 KO cells (5 million) resuspended in 0.2 mL of PBS are subcutaneously implanted into the right flank of each mouse. When the tumor volume reach approximately 50 mm3, the tumor-bearing mice are randomly divided into control and treatment groups (n = 6). The control and treatment groups are administered oral injection of vehicle (0.5% methylcellulose) and Tetrandrine at 30 mg/kg of body weight every other day for 37 days. During the treatment, the tumor volumes are measured every day and are calculated.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang G, et al. Tetrandrine blocks a slow, large-conductance, Ca(2+)-activated potassium channel besides inhibiting a non-inactivating Ca2+ current in isolated nerve terminals of the rat neurohypophysis. Pflugers Arch. 1992 Sep;421(6):558-65. [Content Brief]
[2]. Zhang Z, et al. The plant alkaloid tetrandrine inhibits metastasis via autophagy-dependent Wnt/β-catenin and metastatic tumor antigen 1 signaling in human liver cancer cells. J Exp Clin Cancer Res. 2018 Jan 15;37(1):7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6058 mL | 8.0289 mL | 16.0578 mL | 40.1445 mL |
| 5 mM | 0.3212 mL | 1.6058 mL | 3.2116 mL | 8.0289 mL |